Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1090820X12436602 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-focused insights: how emotional distress shapes immunotherapy response in non-small cell lung cancer.
Transl Lung Cancer Res
December 2024
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Repeat breast-conserving surgery (BCS) for in breast tumor recurrence after initial BCS for ductal carcinoma .
Gland Surg
December 2024
The London Breast Institute, Princess Grace Hospital, London, UK.
Experts Are Debating Whether Some Cancers Shouldn't Be Called That.
JAMA
January 2025
Lead Senior Staff Writer, Medical News & Perspectives, JAMA.
Improving breast cancer treatments using pharmacomicrobiomics.
mBio
January 2025
Center for Gastrointestinal Biology and Disease and Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Tamoxifen is the mainstay treatment for estrogen-positive breast cancer for over half a century. However, a significant proportion of patients experience disease recurrence due to treatment failure attributed to various factors, including disease pathology, genetics, and drug metabolism. Alam et al.
View Article and Find Full Text PDFPatient perspective: Is intensive screening of women at high risk of breast cancer evidence-based medicine or ?
Womens Health (Lond)
January 2025
Department of Pharmacy Practice, Midwestern University College of Pharmacy, Glendale Campus, Glendale, AZ, USA.
In 2023, a breast cancer risk assessment and a subsequent positive test for the BRCA-2 genetic mutation brought me to the uncomfortable intersection of a longstanding career as an advocate for high-quality medical evidence to support shared patient-provider decision making and a new role as a high-risk patient. My search for studies of available risk-management options revealed that the most commonly recommended approach for women with a ⩾20% lifetime breast cancer risk, intensive screening including annual mammography and/or magnetic resonance imaging beginning at age 25-40 years, was supported only by cancer-detection statistics, with almost no evidence on patient-centered outcomes-mortality, physical and psychological morbidity, or quality of life-compared with standard screening or a surgical alternative, bilateral risk-reducing mastectomy. In this commentary, I explore parallels between the use of the intensive screening protocol and another longstanding women's health recommendation based on limited evidence, the use of hormone therapy (HT) for postmenopausal chronic disease prevention, which was sharply curtailed after the publication of the groundbreaking Women's Health Initiative trial in 2002.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!